Pemetrexed prolongs survival in patients with malignant pleural mesothelioma or non-small-cell lung cancer

被引：0
|
作者：
不详
机构：
来源：
Drugs & Therapy Perspectives | 2005年 / 21卷 / 10期
关键词：
D O I：
10.2165/00042310-200521100-00001
中图分类号：
学科分类号：
摘要：
Pemetrexed is a multi-targeted antifolate that inhibits DNA and RNA synthesis. It is used, with cisplatin, in the treatment of malignant pleural mesothelioma (MPM) in patients who are not candidates for surgery and also as second-line monotherapy in locally advanced or metastatic non-small-cell lung cancer (NSCLC). Pemetrexed has favourable tolerability when supplemented with folic acid and cyanocobalamin (vitamin B12). It is clinically active against both MPM and NSCLC, with activity non-inferior to docetaxel in treating refractory or recurrent NSCLC and, with concomitant cisplatin, superior efficacy to single-agent cisplatin in treating unresectable MPM. © 2005 Adis Data Information BV. All rights reserved.
引用
收藏
页码：1 / 4
页数：3
相关论文
共 50 条
  • [21] Surgical intervention for non-small-cell lung cancer with minimal malignant pleural effusion
    Masashi Iwasaki
    Masanori Shimomura
    Shunta Ishihara
    Tadanori Yamaguchi
    Mitsuo Kishimoto
    Tsunehiro Ii
    Masayoshi Inoue
    Surgery Today, 2023, 53 : 655 - 662
  • [22] LIVER TOXICITY AS A PREDICTIVE FACTOR FOR SURVIVAL IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER TREATED WITH PEMETREXED.
    Sakamori, Yuichi
    Kim, Young Hak
    Nagai, Hiroki
    Yoshida, Hironori
    Nakaoku, Takashi
    Yagi, Yoshio
    Mishima, Michiaki
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S485 - S486
  • [23] The impact on survival of positive intraoperative pleural lavage cytology in patients with non-small-cell lung cancer
    Aokage, Keiju
    Yoshida, Junji
    Ishii, Genichiro
    Enatsu, Sotarou
    Hishida, Tomoyuki
    Nishimura, Mitsuyo
    Nishiwaki, Yutaka
    Nagai, Kanji
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2010, 139 (05): : 1246 - U181
  • [24] Accuracy of pleural fluid cytology in patients with malignant pleural effusion from non-small-cell lung cancer, pulmonary metastases and pleural mesothelioma. A case-control study
    Lumachi, F.
    Del Conte, A.
    Sulfaro, S.
    Chiara, G. B.
    Basso, S.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S75 - S75
  • [25] Surgical resection of brain metastases prolongs overall survival in non-small-cell lung cancer
    Yen, Chia-Te
    Wu, Wen-Jui
    Chen, Yen-Ting
    Chang, Wei-Chin
    Yang, Sheng-Hsiung
    Shen, Sheng-Yeh
    Su, Jian
    Chen, Hsuan-Yu
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (12): : 6160 - 6172
  • [26] Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer)
    Tomii, Keisuke
    Kato, Terufumi
    Takahashi, Masashi
    Noma, Satoshi
    Kobashi, Yoichiro
    Enatsu, Sotaro
    Okubo, Sumiko
    Kobayashi, Noriko
    Kudoh, Shoji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (04) : 350 - 356
  • [27] Immune modulatory functions of lurbinectedin in small cell lung cancer and malignant pleural mesothelioma patients
    Cantini, L.
    Dumoulin, D.
    Vink, M.
    Klaase, L.
    Slooff, K.
    Cornelissen, R.
    Mankor, J.
    Dingemans, A-M. C.
    Willemsen, M.
    Aerts, J. G.
    ANNALS OF ONCOLOGY, 2022, 33 : S108 - S108
  • [28] Pemetrexed (Alimta): Advancing the treatment of malignant pleural mesothelioma, non-small cell lung, pancreas, and other cancers - Introduction
    Bunn, PA
    Smith, IE
    SEMINARS IN ONCOLOGY, 2002, 29 (06) : 1 - 2
  • [29] Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non-Small Cell Lung Cancer
    Dickgreber, Nicolas J.
    Fink, Thomas H.
    Latz, Jane E.
    Hossain, Anwar M.
    Musib, Luna C.
    Thomas, Michael
    CLINICAL CANCER RESEARCH, 2009, 15 (01) : 382 - 389
  • [30] Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines
    Naga, Shinjiro
    Takenaka, Kazumasa
    Sonobe, Makoto
    Wada, Hiromi
    Tanaka, Fumihiro
    CHEMOTHERAPY, 2008, 54 (03) : 166 - 175
12345